Sirniö, P., Väyrynen, J., Klintrup, K., Mäkelä, J., Mäkinen, M., Karttunen, T., Tuomisto, A. (2017) Decreased serum apolipoprotein A1 levels are associated with poor survival and systemic inflammatory response in colorectal cancer. Scientific Reports, 7 (1). doi:10.1038/s41598-017-05415-9
Decreased serum apolipoprotein A1 levels are associated with poor survival and systemic inflammatory response in colorectal cancer
|Author:||Sirniö, Päivi1; Väyrynen, Juha P.1,2; Klintrup, Kai2,3;|
1Cancer and Translational Medicine Research Unit, University of Oulu
2Oulu University Hospital and Medical Research Center Oulu
3Research Unit of Surgery, Anesthesia and Intensive Care, University of Oulu
|Online Access:||PDF Full Text (PDF, 1.3 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2017111050577
|Publish Date:|| 2017-11-10
Recent studies have reported of an association between high serum apolipoprotein A1 (APOA1) levels and favorable prognosis in several malignancies, while the significance of apolipoprotein B (APOB) in cancer is less well-known. In this study, we analyzed the correlation between serum APOA1 and APOB levels, and APOB/APOA1 ratio, and their associations with clinicopathologic parameters, the levels of twenty systemic inflammatory markers, and survival in 144 colorectal cancer (CRC) patients. We demonstrated that low serum APOA1 levels associated with advanced T-class and TNM-stage but low serum APOB levels did not significantly correlate with tumor characteristics. Serum APOA1 levels showed strong negative correlation with the markers of systemic inflammation including serum CRP and interleukin (IL)-8 levels and blood neutrophil count, whereas high serum APOB levels associated with high serum CCL2 levels. High APOA1 and APOB levels and low APOB/APOA1 ratio associated with improved cancer specific and overall survival. APOA1 had independent prognostic value in Cox regression analysis. In conclusion, low serum APOA1 levels are associated with advanced stage and systemic inflammation, while serum APOB does not significantly correlate with tumor stage. Serum APOA1 represents a promising additional prognostic parameter in CRC.
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
This work was supported by grants from Medical Research Center Oulu, Emil Aaltonen Foundation (J.P.V.), and Thelma Mäkikyrö Foundation.
All data generated or analyzed during this study are available from the corresponding author on reasonable request.
© The Author(s) 2017. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.